1. Home
  2. MFIN vs GLSI Comparison

MFIN vs GLSI Comparison

Compare MFIN & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Medallion Financial Corp.

MFIN

Medallion Financial Corp.

HOLD

Current Price

$10.16

Market Cap

220.3M

Sector

Finance

ML Signal

HOLD

Logo Greenwich LifeSciences Inc.

GLSI

Greenwich LifeSciences Inc.

HOLD

Current Price

$21.90

Market Cap

269.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MFIN
GLSI
Founded
1995
2006
Country
United States
United States
Employees
179
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
220.3M
269.1M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
MFIN
GLSI
Price
$10.16
$21.90
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$12.00
$50.00
AVG Volume (30 Days)
131.4K
130.9K
Earning Date
04-29-2026
05-19-2026
Dividend Yield
5.18%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$0.02
N/A
P/E Ratio
$6.21
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.85
$7.78
52 Week High
$11.00
$34.10

Technical Indicators

Market Signals
Indicator
MFIN
GLSI
Relative Strength Index (RSI) 57.90 45.66
Support Level $9.73 $21.16
Resistance Level $10.80 $29.89
Average True Range (ATR) 0.33 2.17
MACD 0.04 0.08
Stochastic Oscillator 69.72 61.02

Price Performance

Historical Comparison
MFIN
GLSI

About MFIN Medallion Financial Corp.

Medallion Financial Corp is a finance company that originates and services loans in various industries. The four operating segments are, (1) recreation, (2) home improvement, (3) commercial and (4) taxi medallion The company generates maximum revenue from the Recreation segment. The company's geographic Concentrations are in united states diversified in California, Wisconsin, New York, Texas and others.

About GLSI Greenwich LifeSciences Inc.

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers.

Share on Social Networks: